索拉非尼（多吉美）与分化型甲状腺癌。有毒性，且无生存改善的证据。
Sorafenib (NEXAVAR) and differentiated thyroid cancer. Toxic, and no proof of improved survival.
出版信息
Prescrire Int. 2016 Feb;25(168):37.
PMID:27042725
Abstract
Radiological progression was delayed by 5 months in one trial, but its design does not allow reliable analysis of survival. Numerous, sometimes serious, adverse effects occurred.
摘要
在一项试验中，放射学进展延迟了5个月，但其设计不允许对生存率进行可靠分析。出现了许多有时甚至很严重的不良反应。
Zotero 插件